Lead Product(s) : CBS004
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : AnaptysBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Anaptys will receive from Centessa an exclusive, global license for ANB101 (CBS004), a potentially best-in-class BDCA2 modulator antibody that targets pDCs and ANB102, an extended half-life BDCA2 modulator.
Product Name : ANB101
Product Type : Other Large Molecule
Upfront Cash : $10.0 million
November 27, 2023
Lead Product(s) : CBS004
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : AnaptysBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement